• Our Company
    • Our story
    • Our vision and strategy
    • Fibrotic lung diseases
    • CEO statement
    • Board of Directors
    • Management
    • Scientific Advisers
    • Contact
    • Work with us
  • Our focus areas
    • Mechanism of Action
    • Severe lung diseases
    • Role of the renin-angiotensin system
    • Role of the AT2 receptor
  • Our programs
    • Pipeline
  • Investors
    • Listing prospectus
    • Overview
    • Press releases
    • The share
      • Share monitor
      • Largest shareholders
      • Share issues
      • Share capital development
      • Analyst coverage
    • Financial reports
    • Financial calendar
    • Events & Presentations
    • Corporate governance
      • General meeting
      • Nomination committeé
      • Board of Directors
      • Audit Committee
      • Remuneration Committee
      • Scientific committee
      • Management
      • Remuneration and incentives
      • Auditors
      • Scientific Advisers
      • Articles of association
    • Image bank
    • Subscribe for press releases
    • Investor Relations contact
  • Investerare (SE)
    • Listningsprospekt
    • Översikt
    • Pressmeddelanden
    • Aktien
      • Aktiekursgraf
      • Största aktieägare
      • Aktiekapitalets utveckling
      • Emissioner
      • Analytiker
    • Finansiella rapporter
    • Finansiell kalender
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsstämma
      • Valberedning
      • Styrelsen
      • Revisionsutskott
      • Ersättningsutskott
      • Vetenskapligt utskott
      • Ledning
      • Arvoden och ersättningar
      • Revisorer
      • Vetenskapligt råd
      • Bolagsordning
    • Bildbank
    • Prenumerera på nyheter
    • Investerarkontakt
  • Patients and families
    • Disease background
    • Patient story
    • Resources and patient organizations
    • Working with patient groups
    • Access policy
    • Our commitment
logo
  • Our Company
    • Our story
    • Our vision and strategy
    • Fibrotic lung diseases
    • CEO statement
    • Board of Directors
    • Management
    • Scientific Advisers
    • Contact
    • Work with us
  • Our focus areas
    • Mechanism of Action
    • Severe lung diseases
    • Role of the renin-angiotensin system
    • Role of the AT2 receptor
  • Our programs
    • Pipeline
Investors Investerare (SE)
  • Patients and families
    • Disease background
    • Patient story
    • Resources and patient organizations
    • Working with patient groups
    • Access policy
    • Our commitment
logo
Home / Investors / Listing prospectus
Overview Press releases
  • The share
    • Share monitor
    • Largest shareholders
    • Share issues
    • Share capital development
    • Analyst coverage
    • Listing prospectus
Financial reports Financial calendar Events & Presentations
  • Corporate governance
    • Corporate governance reports
    • General meeting
    • Nomination committeé
    • Board of Directors
    • Audit Committee
    • Remuneration Committee
    • Scientific committee
    • Management
    • Remuneration and incentives
    • Auditors
    • Scientific Advisers
    • Articles of association
Image bank Subscribe for press releases Investor Relations contact

Listing prospectus

Vicore Pharma prepared a prospectus in connection with the listing of the company’s shares on Nasdaq Stockholm’s main market on September 27, 2019. The last day of trading on Nasdaq First North Growth Market was September 26.

The prospectus is only available in Swedish.

Vicore Pharma Holding Prospectus

logo
Vicore Pharma’s offices

Kronhusgatan 11
411 05 Göteborg, Sweden

Kornhamnstorg 53
SE-111 27 Stockholm, Sweden

Agern Allé 5A
DK-2970 Hørsholm, Denmark

We'd love to hear from you!
Phone: +46 (0) 31 788 05 60 Mail: info@vicorepharma.com
Quick links
Contact Subscribe for press releases Privacy Policy Cookies